We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

This writer noticed that UK stock investors have been buying an obscure share that fell 26% yesterday but is still up nearly ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable semaglutide, the active ingredient in weight loss juggernauts Wegovy and ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Follow along for live updates on stocks, bonds and other markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 27.6% in the afternoon session after the company delivered mixed fourth-quarter 2024 results: It added fewer customers than expected, ...